News & Updates

Show Multimedia Only

Liver metastasis, tumour size predict recurrence in mRCC after surgery

29 Oct 2025

In patients with synchronous metastatic renal cell carcinoma (mRCC), factors such as liver metastasis, increasing primary tumour size, and elevated preoperative C-reactive protein (CRP) predict the risk of first-year progression following cytoreductive nephrectomy and complete metastasectomy, suggests a recent study.

Liver metastasis, tumour size predict recurrence in mRCC after surgery

29 Oct 2025

[Infographics] Expanding roles of semaglutide in CKM syndrome

23 Oct 2025

Semaglutide is a key organ-protective medication for managing cardio-kidney-metabolic (CKM) syndrome. Discover more about positive trial results across seven key components of CKM syndrome, and upcoming data on semaglutide.

[Infographics] Expanding roles of semaglutide in CKM syndrome

23 Oct 2025

CORE model outperforms FIB-4 in predicting liver-related outcomes

22 Oct 2025 by

A novel risk score, named Cirrhosis Outcome Risk Estimator (CORE), performs better than FIB-4 in predicting liver-related outcomes in the general population, a study has shown. This model is based on a flexible modelling approach and utilizes biomarkers that are easily accessible in primary care.

CORE model outperforms FIB-4 in predicting liver-related outcomes

22 Oct 2025

Even low alcohol intake detrimental to East Asian men with MASLD

22 Oct 2025

Intake of even small amounts of alcohol appears to pose a significant health risk for East Asian men with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a South Korean nationwide cohort study.

Even low alcohol intake detrimental to East Asian men with MASLD

22 Oct 2025

Inherited risk predicts increases in fibrosis in MASLD patients

15 Oct 2025

Genetic risk score (GRS), polygenic risk score-hepatic fat content (PRS-HFC), its adjusted version (PRS-5), and PNPLA3 genotypes alone show a significant relationship with increased fibrosis severity per decade in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), reports a study.

Inherited risk predicts increases in fibrosis in MASLD patients

15 Oct 2025

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

08 Oct 2025

Adding liver-directed radiation therapy (RT) to atezolizumab and bevacizumab (A/B) produces limited additional toxicity with higher response rates among patients with hepatocellular carcinoma (HCC), reports a recent study. However, substantial differences in baseline characteristics hinder a full interpretation of this data.

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

08 Oct 2025

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

02 Oct 2025

The use of direct oral anticoagulants (DOACs) appears to be safer than warfarin for patients with nonvalvular atrial fibrillation (AF) and liver cirrhosis (LC), suggests a study. This is particularly true to reducing the risk of major bleeding in those with Child-Pugh class A disease.

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

02 Oct 2025

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

24 Sep 2025

Metabolic dysfunction–associated steatotic liver disease (MASLD) can lead to the development of metabolic dysfunction–associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma (HCC). Hong Kong studies show that sodium-glucose cotransporter 2 inhibitors (SGLT2i), such as empagliflozin, can reduce liver fat in nondiabetic patients with MASLD and lower the risk of HCC in patients with coexisting type 2 diabetes (T2D) and chronic hepatitis B (CHB).

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

24 Sep 2025

Clinical research in non-university public hospitals correlated with improved patient outcomes

19 Sep 2025 by

More than 10 percent of full-time clinicians in Hong Kong’s non-university public hospitals engaged in original research as principal investigators (PIs), contributing to nearly one-third of the city’s peer-reviewed studies published in 2016–2021. Their clinical research activity is correlated with improved patient outcomes.

Clinical research in non-university public hospitals correlated with improved patient outcomes

19 Sep 2025

LTSG delivers durable weight loss, improves metabolic syndrome

18 Sep 2025

Simultaneous liver transplantation (LT) and sleeve gastrectomy (SG) is effective in sustaining weight loss, managing diabetes and hypertension, and preventing recurrence of steatosis and possibly fibrosis compared with LT alone, suggests a study.

LTSG delivers durable weight loss, improves metabolic syndrome

18 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

Liver metastasis, tumour size predict recurrence in mRCC after surgery

Liver metastasis, tumour size predict recurrence in mRCC after surgery

[Infographics] Expanding roles of semaglutide in CKM syndrome

[Infographics] Expanding roles of semaglutide in CKM syndrome

CORE model outperforms FIB-4 in predicting liver-related outcomes

CORE model outperforms FIB-4 in predicting liver-related outcomes

Even low alcohol intake detrimental to East Asian men with MASLD

Even low alcohol intake detrimental to East Asian men with MASLD

Inherited risk predicts increases in fibrosis in MASLD patients

Inherited risk predicts increases in fibrosis in MASLD patients

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

Liver-directed RT plus atezolizumab-bevacizumab improves response rates in HCC patients

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

DOAC vs warfarin: Which agent is safer for AF patients with cirrhosis?

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

HK studies: SGLT2i reduce liver fat in nondiabetic MASLD, lower HCC risk in T2D + CHB

Clinical research in non-university public hospitals correlated with improved patient outcomes

Clinical research in non-university public hospitals correlated with improved patient outcomes

LTSG delivers durable weight loss, improves metabolic syndrome

LTSG delivers durable weight loss, improves metabolic syndrome